Nikolay Storonsky, the billionaire CEO of fintech giant Revolut, has officially corrected corporate records to reaffirm his UK residency, following a brief filing that listed him in the UAE—a move that had sent shockwaves through regulators and political circles.
A UK tribunal has allowed a massive lawsuit accusing Valve of anti-competitive practices to proceed, drawing vocal support from Epic Games CEO Tim Sweeney, who calls Steam the last major platform clinging to restrictive payment rules.
Despite a slight uptick in earnings per share, CDW Corporation's stock has plummeted over 38% in three years, starkly underperforming a surging market and leaving investors questioning the disconnect between financial performance and share price.
Despite CEO Elon Musk's bold pronouncements on AI, robotics, and a future of 'Amazing Abundance,' Tesla faces mounting pressure from declining automotive revenues and margins. As the company pivots with massive capital expenditure, investors are left weighing futuristic promises against present-day financial headwinds.
A new Morgan Stanley report indicates Amazon is in early discussions with select shippers about its planned Less-Than-Truckload service, set to launch this summer, posing a potential long-term challenge to established carriers.
Shares of the staffing leader surged after its Q4 earnings hinted at a potential end to a multi-year slump, with management pointing to positive sequential growth for the first time since 2021.
Salesforce secures a potential 10-year, $5.6 billion IDIQ contract with the U.S. Army, a strategic win for its national security unit. Yet, analysts caution the headline figure is a ceiling, not a guarantee, with real value hinging on future task orders and AI integration.
Exxon Mobil and Chevron reported declines in full-year earnings as a sustained oil surplus pressured prices, though both companies highlighted strategic shifts toward LNG, chemicals, and power projects to fuel future growth.
The doughnut giant has agreed to a multimillion-dollar settlement following a 2024 cyberattack that compromised personal data of current and former staff, though it admits no fault.
While rising crude prices have lifted Occidental Petroleum's stock recently, a mixed earnings performance and a predominantly 'Hold' rating from Wall Street signal lingering skepticism about its near-term trajectory.
Pharmaceutical leader Eli Lilly will build a new manufacturing facility in Lehigh County, marking the largest life sciences investment in Pennsylvania history and bolstering U.S. production of next-generation weight-loss drugs.
Morgan Stanley reaffirms its Overweight rating on Nvidia with a $250 price target, citing the company's systemic advantage through its Vera Rubin platform and robust hyperscaler spending, despite acknowledging competitive and demand risks.
A proposed near-zero payment increase for Medicare Advantage plans by the Trump administration has blindsided Wall Street, erasing billions in market value and raising fears of a prolonged downturn for major health insurers.
Despite a major new Bitcoin purchase, MicroStrategy's stock has plunged to its lowest level since September 2024, as market turbulence and mixed analyst sentiment pressure the crypto-focused software firm ahead of its earnings report.
From a $10 direct listing to a $150 S&P 500 constituent, Palantir's journey has been fueled by the AI boom. As government and commercial demand surge, analysts project staggering growth. But with sky-high valuations, the path forward requires navigating lofty expectations.
The drive-thru coffee chain 7 Brew debuts a monthly rotating menu of featured beverages, starting with five options for February including a new Chocolate Dipped Strawberry Cold Brew, as it leverages its strong rewards membership to boost visit frequency.
American Express reported fourth-quarter earnings that narrowly missed analyst forecasts, yet a modest stock decline reflects investor confidence in its robust guidance and the sustained momentum of its high-end cardmember base.
Eli Lilly announces a massive new manufacturing facility in Pennsylvania, part of a strategic pivot by major drugmakers to onshore production amid trade tensions and soaring demand for weight-loss drugs.
In a significant diplomatic move, Lebanon's Cabinet has approved an agreement to repatriate hundreds of Syrian prisoners, addressing a major point of contention as the two nations navigate a new political reality following the 2024 ouster of Bashar al-Assad.
French biopharma firm Inventiva (ENXTPA:IVA) has delivered a stunning 126% total return to shareholders over the past year, sharply contrasting with losses over a three-year horizon. As the stock experiences short-term pullbacks, analysts debate whether its current €5.23 price reflects future promise or present hype, with a key drug candidate hanging in the balance.
